Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Insignia Pharmaceuticals LLC is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 2 distinct examiners, resulting in an even distribution of the workload. The portfolio is also split across 2 distinct art units, indicating that the company's biotech innovations fall into different technical classifications.
SOROUSH, LAYLA is the busiest examiner for the company, with 1 pending office action. Because there are 2 distinct examiners for these pending actions, each examiner is responsible for a single case. This lack of concentration across examiners and art units requires the company to manage separate prosecution tracks simultaneously within the pharmaceutical sector.
With 2 distinct art units and 2 distinct examiners involved, the company's prosecution is decentralized. This means the company must be prepared for different sets of examiner expectations and art unit cultures. Success in this technology area requires a flexible approach that can address the specific requirements of each individual examiner and their respective administrative units, ensuring that both pending actions are handled with a tailored strategy.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUTTER, GILLIAN A | 1 | 54.5% | +46.2% |
| SOROUSH, LAYLA | 1 | 40.5% | +43.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19079370 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | SOROUSH, LAYLA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19079373 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | HUTTER, GILLIAN A | 76d |
| 19079370 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | SOROUSH, LAYLA | — |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19079373 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | HUTTER, GILLIAN A | 1629 | §112 | Final Rejection | 76d | Pending | Mar 13, 2025 |
| 19079370 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING OSTEOARTHRITIS | SOROUSH, LAYLA | 1622 | §103§112 | Non-Final OA | — | Pending | Mar 13, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial